Immunic Inc. (IMUX)
| Bid | 0.98 |
| Market Cap | 96.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.4M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1.04 |
| Forward PE | -1.69 |
| Analyst | Buy |
| Ask | 1 |
| Volume | 88,786 |
| Avg. Volume (20D) | 1,707,874 |
| Open | 0.99 |
| Previous Close | 0.98 |
| Day's Range | 0.98 - 0.99 |
| 52-Week Range | 0.56 - 2.11 |
| Beta | 1.39 |
About IMUX
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for IMUX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 week ago · proactiveinvestors.com
Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIImmunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's second quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs. ...
1 week ago · proactiveinvestors.com
Immunic advances MS drug program with Phase 3 trials fully enrolledImmunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning the company for a major data readout by end-2026 in relapsing mult...
1 month ago · proactiveinvestors.com
Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMIImmunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (...
1 month ago · proactiveinvestors.com
Immunic reveals long-term data supporting potential of MS drug vidofludimus calciumImmunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to help patients with relapsing-remitting multiple scler...
1 month ago · proactiveinvestors.com
Immunic showcases MS drug data at BIO International Convention in Boston - ICYMIImmunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company's participation at the BIO International Convention in Boston and recent clinical developments. T...
2 months ago · seekingalpha.com
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears UnwarrantedImmunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's s...
2 months ago · proactiveinvestors.com
Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMIImmunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for its Phase 3 ENSURE program targeting relapsing mult...
2 months ago · proactiveinvestors.com
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trialsImmunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE...
2 months ago · proactiveinvestors.com
Immunic raises $65M in public offering to fund clinical trialsImmunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offe...
2 months ago · proactiveinvestors.com
Immunic unveils pricing of $65M underwritten public offeringImmunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65 million in gross proceeds, which the company plans ...